1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Bioray Biotech Co., Ltd

Bioray Biotech Co., Ltd

TTPEX:7561
17.75
TWD
-0.80
(-4.31%)
534.01MMarket Cap
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
5.83
8.32
6.64
5.7
5.53
6.8
6.38
6.76
7.53
- -
Basic EPS, GAAP
0.16
0.98
0.71
- -
-0.27
0.02
-0.38
0.03
1.09
- -
Free Cash Flow per Basic Share
-1.02
-1.79
-0.05
-1.81
-0.25
-2.07
-0.36
0.45
2.41
- -
Dividend per Share
0.31
- -
0.36
0.29
- -
- -
0.2
- -
- -
- -
Book Value per Share
8
13.59
13.78
13.47
13.28
15.01
14.42
14.22
15.31
14.57
Tangible Book Value per Share
7.9
13.57
13.69
13.36
13.16
14.9
14.38
14.19
15.3
14.56
Basic Weighted Avg Shares
21
22
27
27
27
28
30
30
30
30
Sales/Revenue/Turnover
124
185
182
156
148
191
192
202
223
- -
Operating Margin (%)
-0.31
6.9
3.72
0.06
-5.48
-0.12
-10.08
-1.93
16.97
- -
Depreciation Expense
10
10
15
15
19
22
25
25
24
- -
Net Income, GAAP
3
22
19
- -
-7
1
-12
1
32
- -
Effective Tax Rate (%)
65
14.49
36.78
- -
- -
26.69
- -
27.39
21.8
- -
Profit Margin (%)
2.79
11.72
10.71
-0.04
-4.86
0.26
-6.03
0.5
14.48
- -
Working Capital
194
292
203
153
141
182
173
262
279
260
LT Debt
- -
4
31
29
25
79
66
79
43
63
Total Equity
243
385
382
372
364
451
434
421
453
431
Return on Invested Capital (%)
- -
3.31
1.01
- -
- -
-0.05
- -
-0.62
5.86
- -
Return on Capital (%)
- -
7.39
6.13
- -
- -
0.31
- -
0.39
6.51
- -
Return on Common Equity (%)
- -
7.35
5.19
-0.02
-1.96
0.12
-2.61
0.23
7.38
- -

Capital Structure

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
8
3
8
LT Borrowings
- -
- -
- -
LT Finance Leases
43
43
63
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
30
30
30
Market Capitalization
676
618
534

Working Capital

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
294
320
330
Cash, Cash Equivalents & STI
155
205
209
Accounts Receivable, Net
59
26
32
Inventories
56
62
64
Total Current Liabilities
41
41
70
Payables & Accruals
- -
- -
- -
ST Debt
8
3
8
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
4.54%
7.67%
Free Cash Flow
- -
161.41%
433.43%
Net Income, GAAP
- -
2,557.88%
3,118.56%
Sales/Revenue/Turnover
- -
7.94%
10.42%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
202
2025
- -
- -
223
2026
- -
- -
- -

Semi-annual Earnings Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
0.03
2025
- -
- -
1.09
2026
- -
- -
- -

Semi-annual Dividends Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Chun Mei Lue
Full Time Employees
79
Sector
Health technology
Industry
Biotechnology
Address
No. 21-3, Shennong East Road Tainan City TQ Taiwan 90846
IPO Date
Jul 6, 2020
Website
bio-ray.com.tw
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Bioray Biotech Co., Ltd. is dedicated to the research, development, manufacturing, and commercialization of biological and health-enhancing products. The company's portfolio features specialized functional probiotics, unique medicinal fungi, and cutting-edge immune cell preparations. Bioray Biotech further extends its services to include advanced functional medical testing and comprehensive cell storage solutions. Established in 2005, the firm emphasizes a commitment to comprehensive immunity protection and precision medicine, utilizing patented strains and scientific validation to deliver natural, evidence-backed health and wellness solutions. Headquartered in Pingtung, Taiwan, the company also operates a precision testing laboratory and facilities for immune cell therapy.